The revised model was able to reproduce robustly the key features of experiments in sarcoma cells, such as the synergistic induction of E‐cadherin levels upon overexpression of both GRHL2 and miR‐200 (Somarelli et al., 2016), and predicted how epigenetic regulation of GRHL2 can modulate MET. The gene discussed is GRHL2; the disease is sarcoma.